Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Bellicum Pharmaceuticals Inc is a biotechnology business based in the US. Bellicum Pharmaceuticals shares (BLCM) are listed on the NASDAQ and all prices are listed in US Dollars. Bellicum Pharmaceuticals employs 6 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$2.23|
|52-week range||$2.57 - $7.44|
|50-day moving average||$2.94|
|200-day moving average||$3.10|
|Wall St. target price||$4.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.54|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||-18.01%|
|1 month (2021-09-23)||-25.04%|
|3 months (2021-07-23)||-24.41%|
|6 months (2021-04-23)||-29.43%|
|1 year (2020-10-22)||-63.56%|
|2 years (2019-10-22)||182.17%|
|3 years (2018-10-22)||4.95|
|5 years (2016-10-21)||16.87|
Valuing Bellicum Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bellicum Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bellicum Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Bellicum Pharmaceuticals shares trade at around 5x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||$1.2 million|
|Gross profit TTM||$-38,552,000|
|Return on assets TTM||-52.12%|
|Return on equity TTM||-378.68%|
|Market capitalisation||$21.8 million|
TTM: trailing 12 months
There are currently 806,097 Bellicum Pharmaceuticals shares held short by investors – that's known as Bellicum Pharmaceuticals's "short interest". This figure is 23.2% down from 1.0 million last month.
There are a few different ways that this level of interest in shorting Bellicum Pharmaceuticals shares can be evaluated.
Bellicum Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Bellicum Pharmaceuticals shares currently shorted divided by the average quantity of Bellicum Pharmaceuticals shares traded daily (recently around 707102.63157895). Bellicum Pharmaceuticals's SIR currently stands at 1.14. In other words for every 100,000 Bellicum Pharmaceuticals shares traded daily on the market, roughly 1140 shares are currently held short.
However Bellicum Pharmaceuticals's short interest can also be evaluated against the total number of Bellicum Pharmaceuticals shares, or, against the total number of tradable Bellicum Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bellicum Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Bellicum Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1088% of the tradable shares (for every 100,000 tradable Bellicum Pharmaceuticals shares, roughly 109 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bellicum Pharmaceuticals.
Find out more about how you can short Bellicum Pharmaceuticals stock.
We're not expecting Bellicum Pharmaceuticals to pay a dividend over the next 12 months.
Bellicum Pharmaceuticals's shares were split on a 1:10 basis on 5 February 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bellicum Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Bellicum Pharmaceuticals shares which in turn could have impacted Bellicum Pharmaceuticals's share price.
Over the last 12 months, Bellicum Pharmaceuticals's shares have ranged in value from as little as $2.574 up to $7.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bellicum Pharmaceuticals's is 1.7101. This would suggest that Bellicum Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Bellicum Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes when administered after hematopoietic stem cell transplantation in the treatment of hematologic malignancies and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc. ; BioVec Pharma, Inc. ; ARIAD Pharmaceuticals, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.